Fund moves

Amgen (AMGN): Capital Wealth Planning, LLC added to its stake +154K shares

Capital Wealth Planning, LLC added to its stake in Amgen, per its Q4 2024 13F.

1.71M
Shares reported · +154K vs prior quarter
4.1%
Disclosed portfolio weight
$447M
Reported value
Holdings as of
Dec 31, 2024
Filed
Feb 5, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 6, 2024CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  2. Dec 26, 2024FDAFDA drug approval: Wezlana
  3. Jan 6, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  4. Jan 16, 2025FDAFDA drug approval: Lumakras
  5. Jan 16, 2025FDAFDA drug approval: Vectibix
  6. Feb 5, 2025InsiderOfficer sold ~$484K of AMGN shares in the open market

What came next

  1. Feb 7, 2025InsiderOfficer sold ~$7.34M of AMGN shares in the open market
  2. Feb 11, 2025InsiderOfficer sold ~$2.59M of AMGN shares in the open market
  3. Feb 18, 2025InsiderOfficer sold ~$146K of AMGN shares in the open market
  4. Feb 19, 2025Insider · 3 peopleInsiders: 3 sales (~$5.6M)
  5. Feb 21, 2025InsiderOfficer sold ~$7.68M of AMGN shares in the open market
  6. Feb 24, 2025CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
  7. Feb 27, 2025FDARecall: Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative…
  8. Feb 27, 2025FDARecall: Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL single Dose Vial, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solutio…
  9. Apr 7, 2025FDAFDA drug approval: Amjevita
  10. Apr 8, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  11. Apr 11, 2025CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
  12. Apr 15, 2025CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
  13. Apr 16, 2025Congress · 1 personMembers of Congress: 2 purchases
  14. May 2, 2025InsiderOfficer sold ~$280K of AMGN shares in the open market
  15. May 5, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  16. May 14, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  17. May 20, 2025FDAFDA drug approval: Amjevita
  18. May 22, 2025FDAFDA drug approval: Prolia
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Amgen

For Amgen, OQRO holds 6 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

How this filing works

Explore the data

Common questions

What does this filing report about Amgen (AMGN) stock?

Capital Wealth Planning, LLC added to its stake in Amgen, per its Q4 2024 13F. Now 1.71M shares, $447M reported value, 4.1% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Dec 31, 2024. Filed: Feb 5, 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Amgen recently?

For Amgen, OQRO holds 6 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the AMGN page.

Does this mean AMGN stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Amgen

Everything OQRO holds on this company is on its AMGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data